Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Login and Edit functionaility are currrently unavailable.

Cristina Rosa Ferrone, M.D.

Co-Author

This page shows the publications co-authored by Cristina Ferrone and Andrew Warshaw.
Connection Strength

9.053
  1. Pancreatic ductal adenocarcinoma: long-term survival does not equal cure. Surgery. 2012 Sep; 152(3 Suppl 1):S43-9.
    View in: PubMed
    Score: 0.520
  2. Twenty-three years of the Warshaw operation for distal pancreatectomy with preservation of the spleen. Ann Surg. 2011 Jun; 253(6):1136-9.
    View in: PubMed
    Score: 0.482
  3. Perioperative CA19-9 levels can predict stage and survival in patients with resectable pancreatic adenocarcinoma. J Clin Oncol. 2006 Jun 20; 24(18):2897-902.
    View in: PubMed
    Score: 0.342
  4. Validation of a postresection pancreatic adenocarcinoma nomogram for disease-specific survival. J Clin Oncol. 2005 Oct 20; 23(30):7529-35.
    View in: PubMed
    Score: 0.327
  5. A decrease in preoperative to postoperative CA19-9 level is a significant predictor of survival in patients with pancreatic adenocarcinoma. J Clin Oncol. 2005 Jun; 23(16_suppl):4034.
    View in: PubMed
    Score: 0.318
  6. Assessment of the Long-Term Impact of Pancreatoduodenectomy on Health-Related Quality of Life Using the EORTC QLQ-PAN26 Module. Ann Surg Oncol. 2021 Aug; 28(8):4216-4224.
    View in: PubMed
    Score: 0.238
  7. Tumor Microenvironment Immune Response in Pancreatic Ductal Adenocarcinoma Patients Treated With Neoadjuvant Therapy. J Natl Cancer Inst. 2021 02 01; 113(2):182-191.
    View in: PubMed
    Score: 0.236
  8. Conditional Survival in Resected Pancreatic Ductal Adenocarcinoma Patients Treated with Total Neoadjuvant Therapy. J Gastrointest Surg. 2021 Jan 26.
    View in: PubMed
    Score: 0.236
  9. Timing But Not Patterns of Recurrence Is Different Between Node-negative and Node-positive Resected Pancreatic Cancer. Ann Surg. 2020 08; 272(2):357-365.
    View in: PubMed
    Score: 0.228
  10. Predictors of Resectability and Survival in Patients With Borderline and Locally Advanced Pancreatic Cancer who Underwent Neoadjuvant Treatment With FOLFIRINOX. Ann Surg. 2019 04; 269(4):733-740.
    View in: PubMed
    Score: 0.208
  11. Role of Tumor-Associated Macrophages in the Clinical Course of Pancreatic Neuroendocrine Tumors (PanNETs). Clin Cancer Res. 2019 04 15; 25(8):2644-2655.
    View in: PubMed
    Score: 0.205
  12. Timing But Not Patterns of Recurrence Is Different Between Node-negative and Node-positive Resected Pancreatic Cancer. Ann Surg. 2019 Jan 18.
    View in: PubMed
    Score: 0.205
  13. Are Staging Computed Tomography (CT) Scans of the Chest Necessary in Pancreatic Adenocarcinoma? Ann Surg Oncol. 2018 Dec; 25(13):3936-3942.
    View in: PubMed
    Score: 0.201
  14. Staging Laparoscopy Not Only Saves Patients an Incision, But May Also Help Them Live Longer. Ann Surg Oncol. 2018 Apr; 25(4):1009-1016.
    View in: PubMed
    Score: 0.191
  15. Health-related Quality of Life and Functional Outcomes in 5-year Survivors After Pancreaticoduodenectomy. Ann Surg. 2017 10; 266(4):685-692.
    View in: PubMed
    Score: 0.187
  16. Reappraisal of Staging Laparoscopy for Patients with Pancreatic Adenocarcinoma: A Contemporary Analysis of 1001 Patients. Ann Surg Oncol. 2017 Oct; 24(11):3203-3211.
    View in: PubMed
    Score: 0.184
  17. Phosphorylated Histone H3 (PHH3) Is a Superior Proliferation Marker for Prognosis of Pancreatic Neuroendocrine Tumors. Ann Surg Oncol. 2016 12; 23(Suppl 5):609-617.
    View in: PubMed
    Score: 0.168
  18. Intra-pancreatic Distal Bile Duct Carcinoma is Morphologically, Genetically, and Clinically Distinct from Pancreatic Ductal Adenocarcinoma. J Gastrointest Surg. 2016 05; 20(5):953-9.
    View in: PubMed
    Score: 0.168
  19. Operative Versus Nonoperative Management of Nonfunctioning Pancreatic Neuroendocrine Tumors. J Gastrointest Surg. 2016 Feb; 20(2):277-83.
    View in: PubMed
    Score: 0.165
  20. Health Insurance Expansion and Treatment of Pancreatic Cancer: Does Increased Access Lead to Improved Care? J Am Coll Surg. 2015 Dec; 221(6):1015-22.
    View in: PubMed
    Score: 0.163
  21. Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer. Ann Surg. 2015 Jan; 261(1):12-7.
    View in: PubMed
    Score: 0.155
  22. In response to Birgir Gudjonsson, MD. Surgery. 2014 Nov; 156(5):1286.
    View in: PubMed
    Score: 0.152
  23. Lymphoepithelial cysts and cystic lymphangiomas: Under-recognized benign cystic lesions of the pancreas. World J Gastrointest Surg. 2014 Jul 27; 6(7):136-41.
    View in: PubMed
    Score: 0.150
  24. Pancreatic ductal adenocarcinoma: is there a survival difference for R1 resections versus locally advanced unresectable tumors? What is a "true" R0 resection? Ann Surg. 2013 Apr; 257(4):731-6.
    View in: PubMed
    Score: 0.137
  25. Evolution of the Whipple procedure at the Massachusetts General Hospital. Surgery. 2012 Sep; 152(3 Suppl 1):S56-63.
    View in: PubMed
    Score: 0.130
  26. Gallbladder lesions identified on ultrasound. Lessons from the last 10 years. J Gastrointest Surg. 2012 Mar; 16(3):549-53.
    View in: PubMed
    Score: 0.125
  27. Superior prognostic importance of perineural invasion vs. lymph node involvement after curative resection of duodenal adenocarcinoma. J Gastrointest Surg. 2012 Jan; 16(1):113-20; discussion 120.
    View in: PubMed
    Score: 0.124
  28. A duodenal duplication cyst causing recurrent pancreatitis in a young patient. Am Surg. 2011 Sep; 77(9):1267-9.
    View in: PubMed
    Score: 0.123
  29. Metastatic tumors in the pancreas in the modern era. J Am Coll Surg. 2010 Dec; 211(6):749-53.
    View in: PubMed
    Score: 0.117
  30. Cholesterol crystal embolization presenting as either solid or cystic pancreatic lesion. J Surg Oncol. 2010 Nov 01; 102(6):706-8.
    View in: PubMed
    Score: 0.116
  31. Does the mechanism of lymph node invasion affect survival in patients with pancreatic ductal adenocarcinoma? J Gastrointest Surg. 2010 Feb; 14(2):261-7.
    View in: PubMed
    Score: 0.109
  32. Current trends in pancreatic cystic neoplasms. Arch Surg. 2009 May; 144(5):448-54.
    View in: PubMed
    Score: 0.104
  33. Pancreatic fistula rates after 462 distal pancreatectomies: staplers do not decrease fistula rates. J Gastrointest Surg. 2008 Oct; 12(10):1691-7; discussion 1697-8.
    View in: PubMed
    Score: 0.099
  34. "Evolving Trends in Pancreatic Cystic Tumors: A 3-Decade Single-Center Experience with 1290 Resections". Ann Surg. 2021 Aug 04.
    View in: PubMed
    Score: 0.061
  35. Simulated Volume-Based Regionalization of Complex Procedures: Impact on Spatial Access to Care. Ann Surg. 2021 08 01; 274(2):312-318.
    View in: PubMed
    Score: 0.061
  36. Revision of Pancreatic Neck Margins Based on Intraoperative Frozen Section Analysis Is Associated With Improved Survival in Patients Undergoing Pancreatectomy for Ductal Adenocarcinoma. Ann Surg. 2021 08 01; 274(2):e134-e142.
    View in: PubMed
    Score: 0.061
  37. Influence of Klebsiella pneumoniae and quinolone treatment on prognosis in patients with pancreatic cancer. Br J Surg. 2021 06 22; 108(6):709-716.
    View in: PubMed
    Score: 0.061
  38. Pancreatic acinar cell carcinoma: A multi-center series on clinical characteristics and treatment outcomes. Pancreatology. 2021 May 15.
    View in: PubMed
    Score: 0.060
  39. Patient and Caregiver Considerations and Priorities When Selecting Hospitals for Complex Cancer Care. Ann Surg Oncol. 2021 Aug; 28(8):4183-4192.
    View in: PubMed
    Score: 0.059
  40. Influence of Klebsiella pneumoniae and quinolone treatment on prognosis in patients with pancreatic cancer. Br J Surg. 2020 Sep 30.
    View in: PubMed
    Score: 0.058
  41. Neoplastic-Stromal Cell Cross-talk Regulates Matrisome Expression in Pancreatic Cancer. Mol Cancer Res. 2020 12; 18(12):1889-1902.
    View in: PubMed
    Score: 0.057
  42. Risk of malignancy in small pancreatic cysts decreases over time. Pancreatology. 2020 Sep; 20(6):1213-1217.
    View in: PubMed
    Score: 0.057
  43. Evaluation of Pathologic Response on Overall Survival After Neoadjuvant Therapy in Pancreatic Ductal Adenocarcinoma. Pancreas. 2020 08; 49(7):897-903.
    View in: PubMed
    Score: 0.057
  44. A Combination of Biochemical and Pathological Parameters Improves Prediction of Postresection Survival After Preoperative Chemotherapy in Pancreatic Cancer: The PANAMA-score. Ann Surg. 2020 Jul 07.
    View in: PubMed
    Score: 0.057
  45. Reappraising the Concept of Conditional Survival After Pancreatectomy for Ductal Adenocarcinoma: A Bi-institutional Analysis. Ann Surg. 2020 06; 271(6):1148-1155.
    View in: PubMed
    Score: 0.056
  46. An elevated CA 19-9 is associated with invasive cancer and worse survival in IPMN. Pancreatology. 2020 Jun; 20(4):729-735.
    View in: PubMed
    Score: 0.056
  47. Variation in long-term oncologic outcomes by type of cancer center accreditation: An analysis of a SEER-Medicare population with pancreatic cancer. Am J Surg. 2020 07; 220(1):29-34.
    View in: PubMed
    Score: 0.056
  48. Impact of adjuvant therapy in patients with invasive intraductal papillary mucinous neoplasms of the pancreas. Pancreatology. 2020 Jun; 20(4):722-728.
    View in: PubMed
    Score: 0.055
  49. Main Pancreatic Duct to Parenchymal Thickness Ratio at Preoperative Imaging is Associated with Overall Survival in Upfront Resected Pancreatic Cancer. Ann Surg Oncol. 2020 May; 27(5):1606-1612.
    View in: PubMed
    Score: 0.054
  50. Does preoperative pharmacologic prophylaxis reduce the rate of venous thromboembolism in pancreatectomy patients? HPB (Oxford). 2020 07; 22(7):1020-1024.
    View in: PubMed
    Score: 0.054
  51. Diabetes mellitus is associated with unfavorable pathologic features, increased postoperative mortality, and worse long-term survival in resected pancreatic cancer. Pancreatology. 2020 Jan; 20(1):125-131.
    View in: PubMed
    Score: 0.054
  52. Association Between Pancreatic Fistula and Long-term Survival in the Era of Neoadjuvant Chemotherapy. JAMA Surg. 2019 10 01; 154(10):943-951.
    View in: PubMed
    Score: 0.054
  53. Intraoperative Fluid Administration and Surgical Outcomes Following Pancreaticoduodenectomy: External Validation at a Tertiary Referral Center. World J Surg. 2019 Mar; 43(3):929-936.
    View in: PubMed
    Score: 0.052
  54. Lower phosphate levels following pancreatectomy is associated with postoperative pancreatic fistula formation. HPB (Oxford). 2019 07; 21(7):834-840.
    View in: PubMed
    Score: 0.051
  55. Intraoperative Dexamethasone Decreases Infectious Complications After Pancreaticoduodenectomy and is Associated with Long-Term Survival in Pancreatic Cancer. Ann Surg Oncol. 2018 Dec; 25(13):4020-4026.
    View in: PubMed
    Score: 0.050
  56. Major Complications Independently Increase Long-Term Mortality After Pancreatoduodenectomy for Cancer. J Gastrointest Surg. 2019 10; 23(10):1984-1990.
    View in: PubMed
    Score: 0.050
  57. Ductal Carcinoma Arising in a Largely Unchanged Presumed Branch-duct IPMN After 10 Years of Surveillance. Ann Surg. 2017 Dec; 266(6):e38-e40.
    View in: PubMed
    Score: 0.047
  58. Intraductal Papillary Mucinous Neoplasm of the Pancreas in Young Patients: Tumor Biology, Clinical Features, and Survival Outcomes. J Gastrointest Surg. 2018 02; 22(2):226-234.
    View in: PubMed
    Score: 0.047
  59. Diabetes mellitus in intraductal papillary mucinous neoplasm of the pancreas is associated with high-grade dysplasia and invasive carcinoma. Pancreatology. 2017 Nov - Dec; 17(6):920-926.
    View in: PubMed
    Score: 0.047
  60. Tumor engraftment in patient-derived xenografts of pancreatic ductal adenocarcinoma is associated with adverse clinicopathological features and poor survival. PLoS One. 2017; 12(8):e0182855.
    View in: PubMed
    Score: 0.046
  61. Long-term Risk of Pancreatic Malignancy in Patients With Branch Duct Intraductal Papillary Mucinous Neoplasm in a Referral Center. Gastroenterology. 2017 11; 153(5):1284-1294.e1.
    View in: PubMed
    Score: 0.046
  62. Primary lymph node gastrinoma: A single institution experience. Surgery. 2017 11; 162(5):1088-1094.
    View in: PubMed
    Score: 0.046
  63. Potential impact of a volume pledge on spatial access: A population-level analysis of patients undergoing pancreatectomy. Surgery. 2017 08; 162(2):203-210.
    View in: PubMed
    Score: 0.046
  64. Preoperative biliary drainage does not increase major complications in pancreaticoduodenectomy: a large single center experience from the Massachusetts General Hospital. J Hepatobiliary Pancreat Sci. 2016 Mar; 23(3):181-7.
    View in: PubMed
    Score: 0.042
  65. Intraductal papillary mucinous neoplasms of the pancreas with concurrent pancreatic and periampullary neoplasms. Eur J Surg Oncol. 2016 Feb; 42(2):197-204.
    View in: PubMed
    Score: 0.041
  66. Patterns of Recurrence After Resection of IPMN: Who, When, and How? Ann Surg. 2015 Dec; 262(6):1108-14.
    View in: PubMed
    Score: 0.041
  67. Early Drain Removal--The Middle Ground Between the Drain Versus No Drain Debate in Patients Undergoing Pancreaticoduodenectomy: A Prospective Validation Study. Ann Surg. 2015 Aug; 262(2):378-83.
    View in: PubMed
    Score: 0.040
  68. Acute pancreatitis in intraductal papillary mucinous neoplasms: A common predictor of malignant intestinal subtype. Surgery. 2015 Nov; 158(5):1219-25.
    View in: PubMed
    Score: 0.040
  69. Effects of Comorbidities on Outcomes of Patients With Intraductal Papillary Mucinous Neoplasms. Clin Gastroenterol Hepatol. 2015 Oct; 13(10):1816-23.
    View in: PubMed
    Score: 0.040
  70. IPMN involving the main pancreatic duct: biology, epidemiology, and long-term outcomes following resection. Ann Surg. 2015 May; 261(5):976-83.
    View in: PubMed
    Score: 0.040
  71. Oncocytic-type intraductal papillary mucinous neoplasms: a unique malignant pancreatic tumor with good long-term prognosis. J Am Coll Surg. 2015 May; 220(5):839-44.
    View in: PubMed
    Score: 0.039
  72. High performing whipple patients: factors associated with short length of stay after open pancreaticoduodenectomy. J Gastrointest Surg. 2014 Oct; 18(10):1760-9.
    View in: PubMed
    Score: 0.038
  73. Not all mixed-type intraductal papillary mucinous neoplasms behave like main-duct lesions: implications of minimal involvement of the main pancreatic duct. Surgery. 2014 Sep; 156(3):611-21.
    View in: PubMed
    Score: 0.038
  74. Understanding hospital readmissions after pancreaticoduodenectomy: can we prevent them?: a 10-year contemporary experience with 1,173 patients at the Massachusetts General Hospital. J Gastrointest Surg. 2014 Jan; 18(1):137-44; discussion 144-5.
    View in: PubMed
    Score: 0.035
  75. Updated long-term outcomes and prognostic factors for patients with unresectable locally advanced pancreatic cancer treated with intraoperative radiotherapy at the Massachusetts General Hospital, 1978 to 2010. Cancer. 2013 Dec 01; 119(23):4196-204.
    View in: PubMed
    Score: 0.035
  76. Branch duct intraductal papillary mucinous neoplasms: does cyst size change the tip of the scale? A critical analysis of the revised international consensus guidelines in a large single-institutional series. Ann Surg. 2013 Sep; 258(3):466-75.
    View in: PubMed
    Score: 0.035
  77. N0/N1, PNL, or LNR? The effect of lymph node number on accurate survival prediction in pancreatic ductal adenocarcinoma. J Gastrointest Surg. 2013 Feb; 17(2):257-66.
    View in: PubMed
    Score: 0.034
  78. Targeting the MAGE A3 antigen in pancreatic cancer. Surgery. 2012 Sep; 152(3 Suppl 1):S13-8.
    View in: PubMed
    Score: 0.033
  79. 851 resected cystic tumors of the pancreas: a 33-year experience at the Massachusetts General Hospital. Surgery. 2012 Sep; 152(3 Suppl 1):S4-12.
    View in: PubMed
    Score: 0.033
  80. Intraductal papillary mucinous neoplasms: does a family history of pancreatic cancer matter? Pancreatology. 2012 Jul-Aug; 12(4):358-63.
    View in: PubMed
    Score: 0.032
  81. Pancreatic neuroendocrine tumors with involved surgical margins: prognostic factors and the role of adjuvant radiotherapy. Int J Radiat Oncol Biol Phys. 2012 Jul 01; 83(3):e337-43.
    View in: PubMed
    Score: 0.032
  82. Implications of incidentally discovered, nonfunctioning pancreatic endocrine tumors: short-term and long-term patient outcomes. Arch Surg. 2011 May; 146(5):534-8.
    View in: PubMed
    Score: 0.030
  83. Incidental pancreatic cysts: do we really know what we are watching? Pancreatology. 2010; 10(2-3):144-50.
    View in: PubMed
    Score: 0.028
  84. Invasive intraductal papillary mucinous carcinomas of the pancreas: predictors of survival and the role of lymph node ratio. Ann Surg. 2010 Mar; 251(3):477-82.
    View in: PubMed
    Score: 0.028
  85. Preoperative platelet count and survival prognosis in resected pancreatic ductal adenocarcinoma. World J Surg. 2008 Jun; 32(6):1051-6.
    View in: PubMed
    Score: 0.024
  86. Implications and management of pancreatic fistulas following pancreaticoduodenectomy: the Massachusetts General Hospital experience. Arch Surg. 2008 May; 143(5):476-81.
    View in: PubMed
    Score: 0.024
  87. Improved contemporary surgical management of insulinomas: a 25-year experience at the Massachusetts General Hospital. Ann Surg. 2008 Jan; 247(1):165-72.
    View in: PubMed
    Score: 0.024
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.